Assessment of thiopurine methyltransferase and metabolite formation during thiopurine therapy: Results from a large swedish patient population

Therapeutic Drug Monitoring

Volumn 26, Issue 6, 2004, Pages 673-678

  Hindorf, Ulf ^a   Peterson, Curt ^b   Almer, Sven ^c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Drug monitoring; Methylthioinosine monophosphate (meTIMP); Thioguanine nucleotides (TGN); Thiopurine drugs; Thiopurine methyltransferase (TPMT)

Indexed keywords

AZATHIOPRINE; DRUG METABOLITE; INOSINE DERIVATIVE; MERCAPTOPURINE; METHYLTHIOINOSINE MONOPHOSPHATE; NUCLEOTIDE DERIVATIVE; THIOGUANINE DERIVATIVE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CORRELATION ANALYSIS; CYTOTOXICITY; DOSE RESPONSE; DRUG DNA INTERACTION; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; HUMAN; HUMAN CELL; INFANT; MALE; PRIORITY JOURNAL; SWEDEN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AZATHIOPRINE; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; INFANT; MALE; METHYLTRANSFERASES; MIDDLE AGED; PATIENT SELECTION; SWEDEN;

EID: 9644291462     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200412000-00014     Document Type: Article

References (28)

1. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992;43:329-339.
2. Elion GB. Biochemistry and pharmacology of purine analogues. Fed Proc 1967;26:898-904.
3. Aarbakke J. Biology and pharmacology of thiopurines. Pediatr Hematol Oncol. 1995;12:511-519.
4. Lennard L, Lilleyman JS. Indvidualazing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase polymorphism. Ther Drug Monit. 1996;18:328-334.
5. Guerciolini R, Szumlanski C, Weinshilboum RM. Human liver xantine oxidase: nature and extent of individual variation. Clin Pharmacol Ther. 1991;50:663-672.
6. Zimm S, Collins JM, Riccardi R, et al. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukaemia being optimally delivered? N Engl J Med. 1983;308:1005-1009.
7. Erb N, Harms DO, Janka-Schaub G. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukaemia receiving 6-thioguanine versus 6-mercaptopurine. Cancer Chemother Pharmacol. 1998;42:266-272.
8. Schutz E, von Ahsen N, Oellerich M. Genotyping of eight thiopurine methyltransferase mutations: three-color multiplexing, "two-color/- shared" anchor, and fluorescence-quenching hybridization probe assays based on thermodynamic nearest-neighbor probe design. Clin Chem. 2000;46:1728-1737.
9. Hon YY, Fessing MY, Pui CH, et al. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet. 1999;8:371-376.
10. Schaeffeler E, Stanulla M, Greil J, et al. A novel TPMT missense mutation associated with TPMT deficiency in a 5-year-old boy with ALL. Leukemia. 2003;17:1422-1424.
11. Hamdan-Khalil R, Allorge D, Lo-Guidice JM, et al. In vitro characterization of four novel non-functional variants of the thiopurine S-methyltransferase. Biochem Biophys Res Commun. 2003;309:1005-1010.
12. Lindqvist M, Haglund S, Almer S, et al. Identification of two novel sequence variants affecting thiopurine methyltransferase enzyme activity. Pharmacogenetics. 2004;14:261-265.
13. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32:651-662.
14. Seidman EG. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord. 2003;3[suppl 1]:S30-S38.
15. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease; azathioprine, 6-mercaptopurine, cyclosporine and methotrexate. Am J Gastroenterol. 1996;91:423-433.
16. Weinshilboum RM, Raymond FA, Pazmino PA. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta. 1978;85:323-333.
17. Klemetsdal B, Tollefsen E, Loennechen T, et al. Interethnic difference in thiopurine methyltransferase activity. Clin Pharmacol Ther. 1992;51:24-31.
18. Lennard L, Singleton HJ. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr B. 1992;583:83-90.
19. Pettersson B, Almer S, Albertioni F, et al. Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate. Ther Drug Monit. 2002;24:351-358.
20. Haglund S, Lindqvist M, Almer S, et al. Pyrosequencing of TPMT alleles in a general Swedish population and in patients with inflammatory bowel disease. Clin Chem. 2004;50:288-295.
21. Lennard L, Van Loon JA, Lilleyman JS, et al. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther. 1987;41:18-25.
22. Lennard L, Lilleyman JS, Van Loon J, et al. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 1990;336:225-229.
23. McLeod HL, Relling MV, Liu Q, et al. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukaemia. Blood. 1995;85:1897-1902.
24. Holme SA, Duley JA, Sanderson J, et al. Erythrocyte thiopurine methyl transferase assessment prior to azathioprine use in the UK. Q J Med. 2002;95:439-444.
25. Kaskas B, Louis E, Hindorf U, et al. TPMT-deficient patients with inflammatory bowel disease can be treated safely with azathioprine after dose adjustment. Gut. 2003;52:140-142.
26. Dervieux T, Blanco JG, Krynetski Y, et al. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res. 2001;61:5810-5816.
27. Lennard L, Hale JP, Lilleyman JS. Red blood cell hypoxanthine phosphoribosyltransferase activity measured using 6-mercaptopurine as a substrate: a population study in children with lymphoblastic leukaemia. Br J Clin Pharmacol. 1993;36:277-284.
28. Adamson PC, Balis FM, Steinberg SM, et al. Pharmacokinetics of mercaptopurine in children with acute lymphocytic leukaemia. N Engl J Med. 1990;323:1565-1566.